Nordicus Partners Reports First Revenue but Faces Significant Losses and Cash Flow Challenges

Nordicus Partners Corporation (OTCMKTS: ASNB) has recently released its quarterly income statement for the period ending December 31, 2024, revealing significant operational changes and financial performance metrics.

Key Financial Highlights:

• Revenue: $2,500 for the three months ended December 31, 2024; $0 for the same period in 2023.
• Operating Expenses: Increased significantly to $1,267,810 from $74,990 year-over-year.
• Net Loss: Loss of $1,535,963 compared to a loss of $74,990 in the previous year’s quarter.
• Accumulated Deficit: $46,178,444 as of December 31, 2024.
• Cash: $28,001 at the end of the reporting period, down from $49,933 in the previous quarter.

Positive Aspects:

• Revenue Generation: The company recorded revenue for the first time in this quarter, signifying operational progress.
• Growth in Equity: Additional paid-in capital increased dramatically to $105,072,125 compared to $45,696,761 a year earlier.
• New Acquisitions: Acquired Orocidin A/S and Bio-Convert ApS, potentially diversifying and strengthening their market presence.

Negative Aspects:

• High Operating Losses: The loss from operations was considerable, indicating high costs associated with new business operations and acquisitions.
• Cash Flow Concerns: The company has substantial cash outflows with limited revenue to support ongoing operations, raising questions about its liquidity.
• Warrant Liability Recognition: The recording of a $280,000 liability related to issued warrants may impact future financial metrics and raise concerns among investors.

Nordicus Partners has established a presence in significant biopharmaceutical ventures and is positioned to leverage growth from its recent acquisitions. However, management must efficiently navigate through operational expenses and ensure a sustainable cash flow to mitigate the financial constraints revealed in the latest reports.

For more in-depth analysis, you can explore this link.